http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2750366-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39bf0bb8b07e151d4bcead749d7dd699 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1217 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate | 2013-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2736e68d83c573d195c4b3d5ad945c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_162aaf72d7936cf5fd6865bff9ad9437 |
| publicationDate | 2020-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2750366-T3 |
| titleOfInvention | In vitro potency assay for protein-based meningococcal vaccines |
| abstract | A binding assay for in vitro analysis of a vaccine sample containing meningococcal protein from a final vaccine lot as it would be released to the public, comprising the steps of: (i) allowing a meningococcal protein immunogen within the vaccine it shows an interaction with a monoclonal antibody that (a) is bactericidal for meningococcus or (b) recognizes a conformational epitope on the meningococcal immunogen; then (ii) measure the interaction between the meningococcal immunogen and the antibody from step (i), in which the binding assay is an ELISA, in which the sample is analyzed in the form in which it is taken from the batch, and either at full strength or after dilution, where the vaccine includes the meningococcal pufH antigen, and where the monoclonal antibody used in step (i) that recognizes the meningococcal pufH antigen is selected from: 12C1 / D7, whose VL region has the amino acid sequence of SEQ ID NO: 21 and whose VP region has the amino acid sequence of SEQ ID NO: 22; 11F10 / G6, whose VL region has the amino acid sequence of SEQ ID NO: 23 and whose VP region has the amino acid sequence of SEQ ID NO: 24; 30G11 / H3, whose VL region has the amino acid sequence of SEQ ID NO: 25 and whose VP region has the amino acid sequence of SEQ ID NO: 26; and 14B3 / D4, whose VL region has the amino acid sequence of SEQ ID NO: 27 and whose VP region has the amino acid sequence of SEQ ID NO: 28. |
| priorityDate | 2012-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 235.